Literature DB >> 1491043

Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation.

T Eriksson1, S Björkman, A Fyge, H Ekberg.   

Abstract

Thalidomide was determined in plasma and blood by reversed-phase high-performance liquid chromatography with ultraviolet detection. The coefficient of variation of the assay was 1-2% over the 0.25-4.0 micrograms/ml concentration range. Hydrolysis of thalidomide during storage and work-up of the samples was avoided by the addition of an equal volume of citrate buffer, pH 1.5. The assay could be applied to the determination of blood concentrations of thalidomide in rats for at least 28 h after a single oral dose, with multiple blood sampling from the same animal.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1491043     DOI: 10.1016/0378-4347(92)80321-g

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  A double-blind study of the sedative effects of the thalidomide enantiomers in humans.

Authors:  P Höglund; T Eriksson; S Björkman
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

2.  Protective effect of pentoxifylline plus thalidomide against septic shock in mice.

Authors:  O Arrieta; A Ortiz-Reyes; D Rembao; M Calvillo; E Rivera; J Sotelo
Journal:  Int J Exp Pathol       Date:  1999-02       Impact factor: 1.925

3.  Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity.

Authors:  L G Corral; G W Muller; A L Moreira; Y Chen; M Wu; D Stirling; G Kaplan
Journal:  Mol Med       Date:  1996-07       Impact factor: 6.354

4.  Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.

Authors:  Lissandra Dal Lago; Marc F Richter; Anna I Cancela; Sabrina A Fernandes; Keylla T Jung; Ana C Rodrigues; Teresa Dalla Costa; Luciane P Di Leone; Gilberto Schwartsmann
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 5.  Thalidomide: rationale for renewed use in immunological disorders.

Authors:  U Schuler; G Ehninger
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

6.  Determination of thalidomide concentration in human plasma by liquid chromatography-tandem mass spectrometry.

Authors:  Nan Bai; Xiang-Yong Cui; Jin Wang; Chun-Guang Sun; He-Kun Mei; Bei-Bei Liang; Yun Cai; Xiu-Jie Song; Jing-Kai Gu; Rui Wang
Journal:  Exp Ther Med       Date:  2012-11-30       Impact factor: 2.447

Review 7.  Clinical pharmacokinetics of thalidomide.

Authors:  Steve K Teo; Wayne A Colburn; William G Tracewell; Karin A Kook; David I Stirling; Markian S Jaworsky; Michael A Scheffler; Steve D Thomas; Oscar L Laskin
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 5.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.